Eric A. Rose M.D. ( Chief Executive Officer and Chairman)
Daniel J. Luckshire ( Principal Financial Officer and Chief Financial Officer)

SIGA Technologies, Inc. (OTC Pink: SIGAQ) is a pharmaceutical company set up in 1995 that is now based in New York City. The company markets pharmaceutical solutions for smallpox, Ebola, dengue, Lassa fever, and other lethal disease-causing pathogens.

SIGA has strong relationship with federal agencies and academic laboratories for its research and development activities. SIGA is providing countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD), such as Category A pathogens using BSL-3 or -4 work.

SIGA’s antiviral programs produce products to prevent pathogens and biodefense threats, using the robotics in the chemical compound library. The company’s bioinformatics infrastructure provides biological and chemical data and software platform for researchers to management and study (such as data mining). The current discovery targets are influenza virus (H5N1, H2N1), Bunyavirus (Rift Valley Fever virus, La Crosse virus), filovirus (Marburg virus, Ebola virus), flavivirus (West Nile virus).

In September 2009, SIGA Technologies received a $1.6 million research fund from the National Institutes of Health ("NIH") for its broad-spectrum antiviral candidates.

In August 2011, SIGA Technologies was awarded a $7.7 million grant from the National Institutes of Health (NIH) to develop an antiviral drug for treating and preventing Lassa fever and others of Arenavirus origin.

In 2011, SIGA was ordered to pay $232 million in damages in a legal dispute with PharmAthene over rights to the smallpox drug tecovirimat.

In July 2013, SIGA Technologies delivered about 590,000 courses of its smallpox antiviral drug tecovirimat (Arestvy) to the United States Government's Strategic National Stockpile (SNS), meeting the requirement of Government's Biomedical Advanced Research and Development Authority (BARDA).

In November 2013, SIGA laid off its entire research & development division located in Corvallis, Oregon. The company liquidated all laboratory equipment at auction from that site.

SIGA is a member of the Alliance for Biosecurity. The alliance is a public-private partnership and coalition of biopharmaceutical companies and academic organizations that promotes that works to ensure medical countermeasures are available to protect public health and improve national health security.

In 2014, SIGA filed for bankruptcy protection.

SIGA’s products include tecovirimat (Arestvyr, ST-246), an orally administered antiviral drug for orthopoxviruses; anti-arenavirus drug for hemorrhagic fever classified as Category A agents by the Centers for Disease Control and Prevention; anti-Orthopoxvirus Drug; Dengue Antiviral; Broad Spectrum Antiviral, screening for antivirals against Category A and B pathogens.

In 2008, the company was selected as a winner of the Deloitte New York, New Jersey, Connecticut Technology Fast 50 Program for 2008, as a four-time winner of the reward.